Bioscience Company Announces FDA Approval For Ovarian Cancer Treatment

Anixa Biosciences Inc. (NASDAQ: ANIX) recently announced a milestone in its collaborative efforts with Moffitt Cancer Center. The U.S. Food and Drug Administration (FDA) has granted approval for an individual patient Investigational New Drug Application (IND), allowing the administration of a second dose of its CAR-T therapy for a patient who has shown potential clinical activity following the initial treatment. This development represents a promising advancement in the treatment of recurrent ovarian cancer, particularly for patients who have exhausted standard-of-care therapies. $Anixa Biosciences (ANIX.US)$